OBESITY, ENDOMETRIOSIS, AND GLP-1 RECEPTOR AGONISTS: A NARRATIVE REVIEW

OBESITY, ENDOMETRIOSIS, AND GLP-1 RECEPTOR AGONISTS: A NARRATIVE REVIEW DOI: https://doi.org/10.31435/ijitss.3(51).2026.6411Keywords: Obesity, Endometriosis, GLP-1 Receptor Agonists, InflammationAbstract Endometriosis is a chronic, estrogen-dependent inflammatory disease affecting approximately 10% of women of reproductive age and is one of the leading causes of chronic pelvic pain and infertility. The relationship between obesity and endometriosis remains controversial. Although epidemiological studies indicate that endometriosis is diagnosed less frequently in women with a higher body mass index (BMI), excessive adipose tissue may promote disease progression through hormonal disturbances, chronic inflammation, and altered metabolic activity of adipose tissue. This review summarizes the current evidence regarding the mechanisms linking obesity and endometriosis and discusses the potential role of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in the treatment of this disease. In addition to their well-established efficacy in the management of obesity and type 2 diabetes, GLP-1RAs have been shown to promote weight loss, improve metabolic parameters, and reduce chronic inflammation. Available experimental and observational evidence suggests that these mechanisms may indirectly influence the course of endometriosis by modulating the chronic inflammation and the metabolic disturbances associated with obesity. To date, no randomized clinical trials have evaluated the efficacy of GLP-1 receptor agonists in women with endometriosis, and most of the available evidence is derived from preclinical studies, observational studies, and analyses conducted in patients with polycystic ovary syndrome (PCOS). Current evidence suggests that GLP-1RAs represent a promising area of research; however, their role in the treatment of endometriosis requires confirmation in well-designed clinical trials. References Alharbi, S. H. (2024). Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Therapeutic Advances in Endocrinology and Metabolism, 15, Article 20420188231222367. Baxter, S. M., Lund, L. C., Andersen, J. H., Brix, T. H., Hegedüs, L., Hsieh, M. H. C., Su, C. T. T., Cheng, M. C. Y., Chang, Z. C. J., Lai, E. C. C., Hussain, S., Chu, C., Gomes, T., Antoniou, T., Eskander, A., Bouck, Z., Tadrous, M., Bea, S., Choi, E. Y., … Pottegård, A. (2025). Glucagon-like peptide 1 receptor agonists and risk of thyroid cancer: An international multisite cohort study. Thyroid, 35(1), 69–78. Becker, C. M., Bokor, A., Heikinheimo, O., Horne, A., Jansen, F., Kiesel, L., King, K., Kvaskoff, M., Nap, A., Petersen, K., Saridogan, E., Tomassetti, C., van Hanegem, N., Vulliemoz, N., & Vermeulen, N. (2022). ESHRE guideline: Endometriosis. Human Reproduction Open, 2022(2), hoac009. Blüher, M. (2019). Obesity: Global epidemiology and pathogenesis. Nature Reviews Endocrinology, 15(5), 288–298. Bulun, S. E., Yilmaz, B. D., Sison, C., Miyazaki, K., Bernardi, L., Liu, S., Kohlmeier, A., Yin, P., Milad, M., & Wei, J. J. (2019). Endometriosis. Endocrine Reviews, 40(4), 1048–1079. Capobianco, A., & Rovere-Querini, P. (2013). Endometriosis, a disease of the macrophage. Frontiers in Immunology, 4, 9. Chen, H., Lei, X., Yang, Z., Xu, Y., Liu, D., Wang, C., & Du, H. (2025). Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome: A prospective, randomized, controlled, open-label clinical trial. Reproductive Biology and Endocrinology, 23, Article 108. Desai, S. N., Reed, C. C., Mendez, Y., Yang, Q., & Guan, X. (2026). The hidden link between endometriosis and obesity: A state-of-the-art review. Cureus, 18(2), e102896. Drucker, D. J. (2018). Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabolism, 27(4), 740–756. European Medicines Agency. (2024). Ozempic (semaglutide): Summary of product characteristics. European Medicines Agency. Retrieved from Faculty of Sexual & Reproductive Healthcare. (2025). GLP-1 receptor agonists and contraception. London, UK: Author. Jensterle, M., Kravos, N. A., Pfeifer, M., Kocjan, T., & Janez, A. (2015). A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome. Hormones (Athens), 14(1), 81–90. Krasnyi, A. M., Sadekova, A. A., Smolnova, T. Y., Chursin, V. V., Buralkina, N. A., Chuprynin, V. D., Yarotskaya, E., Pavlovich, S. V., & Sukhikh, G. T. (2022). The levels of ghrelin, glucagon, visfatin and GLP-1 are decreased in the peritoneal fluid of women with endometriosis along with the increased expression of the CD10 protease by the macrophages. International Journal of Molecular Sciences, 23(18), 10361. Lee, Y. S., & Jun, H. S. (2016). Anti-inflammatory effects of GLP-1-based therapies beyond glucose control. Mediators of Inflammation, 2016, 3094642. Leonardi, M., Hicks, C., El-Assaad, F., El-Omar, E., & Condous, G. (2020). Endometriosis and the microbiome: A systematic review. BJOG: An International Journal of Obstetrics and Gynaecology, 127(2), 239–249. Leonardi, M., et al. (2025). Effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on endometriosis symptoms management and quality of life: An international survey study [Preprint]. Authorea. Liu, Y., & Zhang, W. (2017). Association between body mass index and endometriosis risk: A meta-analysis. Oncotarget, 8(29), 46928–46936. Maheshwari, A., Bell, J. L., & Bhattacharya, S. (2020). Body mass index and endometriosis: A systematic review and meta-analysis. Human Reproduction Update, 26(2), 242–257. Müller, T. D., Finan, B., Bloom, S. R., D’Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., Holst, J. J., Langhans, W., Meier, J. J., Nauck, M. A., Perez-Tilve, D., Pocai, A., Reimann, F., Sandoval, D. A., Schwartz, T. W., … Tschoep, M. H. (2019). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, 30, 72–130. Rahman, M. S., Park, Y., Hosseinirad, H., Shin, J. H., & Jeong, J. W. (2025). The interplay between endometriosis and obesity. Trends in Endocrinology & Metabolism, 36(12), 1140–1153. Shah, D. K., Correia, K. F., Vitonis, A. F., & Missmer, S. A. (2013). Body size and endometriosis: results from 20 years of follow-up within the Nurses’ Health Study II prospective cohort. Human Reproduction, 28(7), 1783–1792. Sola-Leyva, A., Pathare, A. D. S., Apostolov, A., Aleksejeva, E., Kask, K., Tammiste, T., Ruiz-Durán, S., Risal, S., Acharya, G., & Salumets, A. (2025). The hidden impact of GLP-1 receptor agonists on endometrial receptivity and implantation. Acta Obstetricia et Gynecologica Scandinavica, 104(2), 258–266. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989–1002. Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F. (2023). GLP-1 receptor agonists for the treatment of obesity: Role as a promising approach. Frontiers in Endocrinology, 14, 1085799. World Health Organization. (2025a, October 15). Endometriosis. World Health Organization. (2025b, December 8). Obesity and overweight. Yari, H., Khodadadi, S., Momen-Heravi, M., & Sahebkar, A. (2024). Anti-inflammatory benefits of semaglutide: State of the art. Journal of Clinical & Translational Endocrinology, 36, 100340. Yen, T. T., Hsieh, T. Y. J., Lee, G. Y., Toy, E. P., Wei, J. C., & Tanner, E. J. (2026). GLP-1 receptor agonists plus progestins and endometrial cancer risk in nonmalignant uterine diseases. JAMA Network Open, 9(2), e2558205. Downloads Published Issue Section License Copyright (c) 2026 Oliwia Wróblewska, Jakub Majewski, Małgorzata Witaszczyk, Zofia Hałabuda, Maria Jędryka, Julia Paczyna, Alicja Benecka, Iwona Kawka-Bryk This work is licensed under a Creative Commons Attribution 4.0 International License. All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles. CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.